



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/64, C12Q 1/37 C12N 9/50, C07K 15/28	A1	(11) International Publication Number: WO 91/02540 (43) International Publication Date: 7 March 1991 (07.03.91)
(21) International Application Number: PCT/US90/03266 (22) International Filing Date: 8 June 1990 (08.06.90) (30) Priority data: 395,253 16 August 1989 (16.08.89) US (71) Applicant: CETUS CORPORATION [US/US]; 1400 Fifty-Third Street, Emeryville, CA 94608 (US). (72) Inventors: KRIEGLER, Michael, P. ; 1424 Lake Street, San Francisco, CA 94118 (US). PEREZ, Carl, F. ; 2421 Valley Street, Berkeley, CA 94702 (US). (74) Agent: HALLUIN, Albert, P.; Cetus Corporation, 1400 Fifty-Third Street, Emeryville, CA 94608 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i>
(54) Title: COMPOSITIONS FOR THE INHIBITION OF PROTEIN HORMONE FORMATION AND USES THEREOF (57) Abstract Compounds having proteolytic inhibitory activity useful for treating diseases, particularly as applied to the treatment of sepsis, AIDS or autoimmune diseases, resulting from an increase in the circulating level of mature protein hormones derived from the proteolytic cleavage of prohormone precursors, and methods for identifying compounds having the desired inhibitory activity.		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TG	Togo
				US	United States of America

COMPOSITIONS FOR THE INHIBITION OF PROTEIN HORMONE FORMATION AND USES THEREOF

This invention is in the area of immunology/biochemistry, and particularly concerns the development of compositions and methods for identifying inhibitors of protein hormone formation, and prophylactic and therapeutic uses of the inhibitors for treating diseases associated with elevated levels of the hormones. More specifically, the invention facilitates the identification of compounds that may be used to treat a variety of diseases, particularly sepsis, AIDS and autoimmune diseases, and thus affords the physician alternate treatment regimes.

In the United States alone nosocomial bacteremia develops in about 194,000 patients, and of these about 75,000 die. Maki, D.G., 1981, Nosocomial Infect., (Dikson, R.E., Ed.), page 183, Yrke Medical Books, U.S.A.. Most of these deaths are attributable to six major gram-negative bacilli, and these are *Pseudomonas aeruginosa*, *Escherichia coli*, *Proteus*, *Klebsiella*, *Enterobacter* and *Serratia*. The current treatment for bacteremia is the administration of antibiotics which, unfortunately, have limited effectiveness.

The precise pathology of bacteremia is not completely elucidated, nevertheless, it is known that bacterial endotoxins, lipopolysaccharides (LPS), are the primary causative agent. LPS consist of at least three significant antigenic regions, the lipid A, core polysaccharide, and O-specific polysaccharide. The latter is also referred to as O-specific chain or simply O-antigen. The O-specific chain region is a long-chain polysaccharide built up from repeating polysaccharide units. The number of polysaccharide units differs among different bacterial species and may vary from one to as many as six or seven monosaccharide units. While the O-specific chain varies among different gram-negative bacteria, the lipid A and core polysaccharides are similar if not identical.

Since LPS plays a key role in sepsis, a variety of approaches has been pursued to neutralize its activity. Presently, there is considerable work which suggest that antibody to LPS will soon be a valuable clinical adjunct to the standard antibiotic therapy.

LPS initiates a cascade of biochemical events that eventually causes the death of the patient. It is widely believed that the second event, after the introduction of LPS, is the production of tumor necrosis factor (TNF) as a result of LPS stimulation of macrophage cells. Thus, considerable effort has been expended to produce neutralizing antibody to TNF, or other molecules that could inhibit its septic effects. It

is likely that antibody to TNF will have valuable clinical applications. Tracey, *et al.*, 1987, Nature, 330:662.

TNF has been shown to exist in both membrane bound and soluble secreted forms. Decker, *et al.*, 1987, J. of Immunol., 138:957; Kriegler, *et al.*, 1988, Cell, 53:45. Human TNF has been cloned and shown to consist of a 17 kd polypeptide, plus an unusually long 76 amino acid putative signal leader sequence. The 17 kd molecule is a key agent involved in initiating the biochemical cascade responsible for sepsis. It has been proposed by Kriegler, *et al.*, 1988, Cell, 53:45, that TNF may exist as both a membrane bound 26 kd form, and a soluble form corresponding to the 17 kd species. The 26 kd form is the precursor, or prohormone, of the mature 17 kd molecule. It has further been proposed by Kriegler, *et al.* above, that the two forms of TNF may have different biological effects.

It will be appreciated that because TNF plays a key role in causing sepsis that there is a need to identify and develop anti-TNF prophylactics/therapeutics. As mentioned above, anti-TNF antibody appears to be promising, and has been shown to be effective in baboons. However, these studies have involved the use of non-human TNF and non-human TNF antibody. From a practical standpoint non-human anti-TNF antibody will have limited therapeutic application because of immunologic rejection of the antibody by a patient's immune system. Consequently, human antibody, or genetically engineered antibody consisting of the human constant region and the mouse variable region are preferred.

TNF, in addition to playing a critical role in sepsis, has recently been shown to be involved in initiating the expression of human immunodeficiency virus in human cells that carry latent virus. Folks *et al.*, Proc. Natl. Acad. Sci. USA, vol. 86, p. 2365 (1989). Thus, preventing or inhibiting the formation of the 17 kd, or lower molecular weight forms of TNF would be a valuable prophylactic for the treatment of AIDS patients by preventing the expression of virus that is latent in the patient.

TNF also plays a role in various autoimmune diseases, particularly arthritis. Duff, *et al.*, 1987, International Conference on Tumor Necrosis Factor and Related Cytotoxins, vol. 175:10. Thus, compounds or methods for inhibiting TNF action will have considerable application for the treatment of a variety of diseases of immunologic origin.

In addition to antibody, other molecules with TNF inhibitory activity are being sought. Non-antibody TNF inhibitors are described by Seckinger, *et al.*, 1988, J. Exp. Med., 167:151, and Seckinger, *et al.*, 1989, J. Biol. Chem. 264:11966, and in European Patent Application No. 88830365.8, inventors Wallach, *et al.* The inhibitors are present in the urine of febrile patients, and have been purified and shown to have

molecular weights of about 27,000-33,000. To date neither of the inhibitors have been shown to be effective in the treatment of sepsis.

From the foregoing discussion it is apparent that there is a need to identify and develop additional anti-TNF inhibitors, both antibody based or otherwise, that may be efficaciously applied in the treatment of sepsis.

In its most general form, the invention described herein presents methods and compositions for inhibiting the production of the mature form of a protein hormone, preferably of immunologic origin, from its prohormone precursor. These compositions are useful for preventing or treating diseases in patients associated with elevated circulating levels of the mature hormone.

A second object of the invention described herein relates to a method for identifying molecules that inhibit the production of the mature form(s) of TNF. Such inhibitors are distinguishable from both anti-TNF antibody that neutralizes TNF, and anti-LPS antibody that binds to and neutralizes the affects of LPS.

A third object of the invention is a description of a method that can be used to identify prophylactics and/or therapeutics for the treatment of sepsis premised on the ability of these medicaments to interfere with the cleavage of 26 kd TNF prohormone by an enzyme, termed convertase, that cleaves the 26 kd molecule thereby producing lower molecular weight sepsis inducing molecules.

A fourth object of the invention is a description of a method that identifies inhibitors of sepsis that have significant prophylactic and/or therapeutic applications premised on the ability of the inhibitors to interfere with the production of the 17 kd mature form of TNF from its 26 kd precursor by interfering with the activity of a convertase, that removes the 76 amino acid signal sequence from the 26 kd molecule to produce 17 kd TNF.

A fifth object of the invention is a presentation of a class of compounds that are both inhibitors of the convertase and that are effective in the prevention and/or treatment of sepsis. A partial listing of member compounds in this class include anti-convertase antibody, muteins of the prohormone form, and proteins or peptides that compete with the 26 kd form of TNF for binding to the convertase.

A sixth object of the invention is a presentation of preferred prophylactics or therapeutics that inhibit convertase activity, and that are effective in treating sepsis that have the amino acid sequence of TNF corresponding to that recognized by the convertase.

A seventh object of the invention is a description of the convertase that converts the 26 kd TNF molecule to the sepsis inducing form.

These and further objects of the invention will become apparent after a consideration of the detailed description of the invention shown below.

Figure 1, panel A, shows the restriction map of the DNA sequence that encodes 26 kd TNF. Panel B shows a hydrophobicity plot of 26 kd TNF, and panel C shows the DNA and amino acid sequences of the molecule.

Figure 2 shows the conversion of 26 kd TNF by TNF convertase. Lanes A, B, and C show various controls: TNF 6.8 cell lysate (A), 26 kd transcription/translation (B) and incubation (C) controls. Lanes D, E, and F show the conversion of transcription/translation generated 26 kd TNF to predominately 17 kd TNF by convertase present in either HL 60 S-1 cytosol uninduced (D) and induced (E) fractions, or a P-1 pellet fraction prepared from induced cells. G is a blank lane.

Figure 3 shows the effect of convertase inhibitors on the conversion of 26 kd TNF to its lower molecular weight forms as determined by gel electrophoresis. Lanes A,B,C, and D of panel 1 show, respectively; immunprecipitation of a cell lysate of the pFVXM-TNF6 transfected cell line TNF 6.8 (Kriegler, et al., 1988, in *Cell*, 53:45), immunprecipitation of *in vitro* transcribed/translated 26 kd TNF, the effect of (1-((3-((acetyloxy)-7-methoxy-8-oxy-8-oxo-5-thio-1-azabicyclo [4.2.0] oct-2-en-2-yl) carbonyl) morpholine, S,S-dioxide, (6R-cis) on the conversion of 26 kd TNF, and the conversion of 26 kd TNF in the absence of (1-((3-((acetyloxy)-7-methoxy-8-oxy-8-oxo-5-thio-1-azabicyclo [4.2.0] oct-2-en-2-yl) carbonyl) morpholine, S,S-dioxide, (6R-cis). Lanes A and B of panel 2 show, respectively; immunprecipitation of a cell lysate of the pFVXM-TNF6 transfected cell line TNF 6.8 (Kriegler, et al., 1988, in *Cell*, 53:45), and immunprecipitation of *in vitro* transcribed/translated 26 kd TNF. Lanes C and D show the conversion of 26 kd TNF in the presence and absence of 3,4-dichloro-isocoumarin, respectively. Lanes E and F, show the conversion of 26 kd TNF in the presence and absence of elastinal, respectively.

To facilitate understanding the nature and scope of applicant's invention, several definitions regarding various aspects of the invention are presented below. It will be understood, however, that these definitions are general in nature, and encompassed within the definitions are meanings well known to those skilled in the art.

The terms "prohormone", and "mature" hormone" have the following meanings. Prohormone is intended to cover proteins, preferably of immunologic origin, that have a peptide segment of the protein removed during its *in vivo* production. The removal of the peptide yields the "mature" form of the hormone. The preferred embodiment of the invention is the 26 kd TNF prohormone, as discussed in detail below, which is cleaved primarily to a 17 kd mature form. However, other cleavage products are also formed from the prohormone, and these are intended to

come within the meaning of "mature" hormone. Finally, it is important to note, that prohormones in addition to TNF are intended to come within the scope of these definitions and are considered a part of the invention. Exemplary prohormones are the CSFs and IL-1.

5 Sepsis is herein defined to mean a disease resulting from gram positive or gram negative bacterial infection, the latter primarily due to the bacterial endotoxin, lipopolysaccharide (LPS). It can be induced by at least the six major gram-negative bacilli and these are *Pseudomonas aeruginosa*, *Escherichia coli*, *Proteus*, *Klebsiella*, *Enterobacter* and *Serratia*. TNF is one factor that is detectable in the early phase of the
10 disease, and that contributes to its progress. The 17 kd molecule, or shorter muteins known in the art, are the primary active species.

 As used herein, TNF having a molecular weight of about 26,000, refers to the prohormone form of TNF. It is known that the amino-terminal peptide of the prohormone varies in length depending on the species from which it is derived, while
15 the propeptide segment of the molecule is highly conserved. Indeed, in the mouse approximately 86% of the 79 amino acids that makeup the putative leader sequence of the pro-hormone are identical to the 76 known amino acids that comprise the pro-sequence of human TNF. Thus, it will be appreciated by those skilled in the art that when reference is made below to TNF having a molecular weight of about 26,000, that
20 what is indicated is a molecule that is not derived from a particular species and that may have a slightly altered leader sequence compared to the human sequence as is known in the art.

 The term "convertase", or "TNF convertase" is meant to encompass an enzyme normally present in the body that is responsible for cleaving 26 kd TNF to one or more
25 lower molecular weight species. The convertase is substantially membrane associated, although significant activity is located in the cytosol. Another property of the convertase is that it is primarily associated with cells that produce TNF.

 The phrase "membrane associated" as applied to TNF convertase indicates a form of the convertase that is substantially insoluble as indicated by the presence of
30 most of the convertase activity in a 30,000 xg pellet fraction.

 "Recombinant antibody" refers to antibody wherein one portion of each of the amino acid sequences of heavy and light chain is homologous to corresponding sequences in antibody derived from a particular species or belonging to a particular class, while the remaining segment of the chains is homologous to corresponding
35 sequences in another. Most commonly, in a recombinant antibody the variable region of both light and heavy chain mirrors the variable regions of antibody derived from one

species of mammals, while the constant regions are homologous to the sequences in antibody derived from another.

In its most general form, the instant invention concerns methods and compositions for identifying inhibitors of diseases associated with the production of mature hormones from their prohormone forms. The preferred embodiment of a
5 mature hormones from their prohormone forms. The preferred embodiment of a prohormone is 26 kd TNF, which is cleaved to lower molecular weight molecules, particularly one having a molecular weight of 17,000, that are substantially involved in producing sepsis. Thus, inhibitors capable of interfering with the conversion of the 26 kd form of TNF are useful for preventing or treating sepsis.

10 The assays described herein detect the conversion of a prohormone to its mature hormone form, with the preferred embodiment being the enzymatic conversion of the 26 kd molecular weight form of TNF to, preferably, a 17,000 molecular weight form. The enzyme responsible for the conversion is termed a convertase. Thus, the invention is most readily presented in four parts. Part one shows the materials and methods for
15 realizing the 26 kd form of TNF. Part two identifies sources of TNF convertase, and methods for partially purifying the enzyme. Part three describes assays for detecting and identifying various convertase inhibitors. Finally, part four of the invention presents a description of ways of using the inhibitors to treat patients suffering from sepsis. Each of these sections will now be addressed separately.

20 Several patents/patent applications and scientific references are referred to below. The instant invention draws on some of the material and methods shown in these references, and thus it is intended that all of the references, in their entirety, be incorporated by reference.

It is important to note, and it should be stressed that virtually any procedure
25 that enables one to measure the conversion of the 26 kd TNF species can be utilized to identify inhibitors of TNF. Thus, while the recombinant systems described below render the 26 kd molecule obtainable in considerable amounts, and therefore facilitate assaying for TNF inhibitors, it will be appreciated that non-recombinant systems may also be used. For instance, it has been shown that the 26 kd molecule can be identified
30 in stimulated monocytes. This is described by Kriegler, et al., 1988, Cell, 53:45. Thus, a suitable assay procedure is to stimulate monocytes to produce the 26 kd molecule, and then in the presence of the convertase, measure the disappearance of the molecule to a lower molecular weight species, preferable the 17,000 molecular weight species.

35 Regarding the conversion of the 26,000 molecule, the convertase, as will become apparent below, cleaves the molecule at one internal site, and perhaps at several. The major site is at the junction which separates the secreted form of TNF,

that is, the 17,000 molecular weight species, from the leader sequence. The sequence at this junction is -Gln-Ala-Val-Arg-Ser-Ser-. Thus, the major cleavage event occurs between alanine and valine, since valine is known to be the amino terminal amino acid of the 17,000 molecular weight molecule. Several other species of TNF are produced by the convertase, and thus these are the products of secondary cleavage sites.

Regardless of whether the 26,000 molecule is cleaved at one or more sites, in so far as the identification of inhibitors of sepsis is concerned this is of marginal concern since the instant assay can monitor either the inhibition of the conversion of the 26,000 TNF species, or the appearance of a lower molecular weight form.

TNF, either the 26 kd or 17 kd forms, has been cloned and expressed in a number of systems. For instance, the cloning of rabbit TNF is disclosed in EP 146,026, published June 26, 1985 (Dainippon Pharmaceutical Co., Ltd.) and EP 148,311, published July 17, 1985 (Asahi Kasei Kogyo Kabushiki). The cloning of human TNF having 151 and 155 amino acids (2 and 6 less than the native form) is disclosed in EP 155,549, published September 25, 1985 (Dainippon Pharmaceutical Co., Ltd.), and human TNF having 155 amino acids is disclosed in EP 158,286, published October 16, 1985 (Asahi Kasei Kogyo Kabushiki Kaisha) and corresponding GB 1,158,829A, published November 20, 1985. The cloning of mature TNF (157 amino acids) and various modified forms (muteins) thereof is disclosed in EP 168,214, published January 15, 1986 (Genentech) and PCT US 85/01921, filed October 3, 1985, (Cetus Corporation). The latter, PCT 85/01921, corresponds to WO 86/02381.

In addition, U.S. patents No. 4,677,063 and 4,677,064 show cDNA sequences that encode the 26,000 and 17,000 forms of TNF, as well as muteins of these molecules.

The cDNA sequence that encodes the 26 kd TNF species is preferably obtained from the plasmid, pB11, described in WO 86/02381; and U.S. Patents Nos. 4,677,063 and 4,677,064. The plasmid pB11 contains the SV40 promoter in operable linkage to the TNF coding sequence, and thus is useful for expressing the 26 kd TNF species in eukaryotic host cells. Additionally, a second plasmid which contains the entire sequence which encodes the 26 kd TNF species is described in the forgoing U.S. patent application and patents. It is designated pE4. The plasmid pE4 is on deposit with the American Type Culture Collection, Accession No. 39894.

The cDNA sequence that encodes the 26 kd TNF species is present in the plasmid pB11 as a PstI fragment. Thus, it is readily removed and inserted into any one of a number of suitable expression systems. The preferred expression system is

the plasmid pFVXM, which is on deposit with the American Type Culture Collection and has Accession No. 67,103.

pFVXM is a retroviral vector that was derived from the plasmid pEVX described by Kriegler, *et al.*, 1984, in *Cell*, 38:483. pEVX has a Moloney murine leukemia virus derived splice donor site 3' to the 5' - long terminal repeat. It was previously shown that this splice donor sequence decreases the yield of correctly spliced translational templates of retroviral constructions. Thus, pEVX was engineered to remove the splice donor site, and replaced with an analogous Sma I fragment of the Harvey murine sarcoma virus genome, which lacks the Moloney murine leukemia virus splice donor sequence. The resulting vector, pFVXM, lacks the Moloney murine leukemia virus spliced donor sequence and carries a viral packaging sequence. pFVXM has a convenient Pst I site in which the DNA sequences that encodes the 26 kd TNF species can be inserted.

A variety of biological materials are available as sources of convertase activity. These include tissues, cells, or extracts, or fluids associated therewith that are preferably, but not necessarily, of immunologic origin. Moreover, established cell lines may also be utilized. Suitable sources would include human peripheral blood mononuclear cells, such as leukocytes or cell lines of leukocyte origin, preferably the cell line HL60. Because of the ease of manipulating established cell lines, the preferred source of the convertase is HL60. Thus, the conversion of the 26 kd TNF species to the 17 kd species can be affected by combining the 26 kd species with either intact HL60 cells, extracts derived therefrom, or media in which the HL60 cells were grown and thus contains convertase activity. In some cell types, convertase activity is present in the culture medium after the appropriate stimulation, which is discussed more below. Further, because the convertase activity is partially membrane associated, it is possible to obtain a membrane fraction that may be utilized.

The procedures for isolating monocytes are well known in the art, as are other methods for culturing cell lines such as HL60. Briefly, monocytes may be prepared from peripheral blood by centrifugation first through Ficoll-paque and percoll (49.2%) using standard procedures. This yields an enriched population of monocytes and lymphocytes, and the monocytes can be further enriched by plating the mixture of cells onto tissue culture dishes and incubating the cells for a time sufficient to permit the monocytes to adhere to the surface of the dishes. The lymphocytes are then washed off of the plates leaving only adherent monocytes. These cells may then be used as is, or can be stimulated to produce enhanced levels of convertase using known monocytes activators, preferably lipopolysaccharide and phorbol myristate acetate. The cells may

be fractionated, and either an extract or a membrane fraction prepared therefrom and employed in the assays described below.

Inhibitors of convertase activity will also be prophylactics or therapeutics that may be used in the treatment of sepsis. They may be identified using the foregoing assay, and further including in the assay reaction mixture compounds sought to be tested for inhibitory activity. A suitable assay would consist of combining 26 kd TNF, the convertase, and a putative inhibitor. It will be understood by those skilled in the art that the inhibitory material may be added to the convertase before the convertase is added to TNF, or it can be added to TNF prior to, or immediately after adding the convertase. The order of addition may facilitate identification of inhibitors, but it is not determinative. If a substance has inhibitory activity, this can be revealed by electrophoretic analysis of the solution which will reveal a reduction in the amount of the 26 kd species, and concomitantly the presence of lower molecular weight TNF molecules.

In addition to identifying compounds with unsuspected anti-convertase activity, several compounds will have strong inhibitory activity such as anti-convertase antibody, either polyclonal or monoclonal, or recombinant antibody, preferably humanized. Monoclonal antibody to the convertase may be produced using the general procedures described by Kohler, G. and Milstein, C., 1975, *Nature*, 256:495, which have been modified over the years as is known in the art. These initial studies involved fusing murine lymphocytes and drug selectable plasmacytomas to produce hybridomas. Subsequently, the technique has been applied to produce hybrid cell lines that secrete human monoclonal antibodies. The latter procedures are generally described in Abrams, P., 1986, *Methods in Enzymology*, 121:107, but other modifications are known to those skilled in the art. Regardless of whether murine or human antibody is produced, the antibody secreting cells are combined with the fusion partner and the cells fused with a suitable fusing agent, preferably polyethylene glycol, and more preferably polyethylene glycol 1000. The latter is added to a cell pellet containing the antibody secreting cells and the fusion partner in small amounts over a short period of time accompanied with gentle agitation. After the addition of the fusing agent, the cell mixture is washed to remove the fusing agent and any cellular debris, and the cell mixture consisting of fused and unfused cells seeded into appropriate cell culture chambers containing selective growth media. After a period of several weeks, hybrid cells are apparent, and may be identified as to antibody production and subcloned to ensure the availability of a stable hybrid cell line.

The preferred antibody is human monoclonal antibody which can be prepared from lymphocytes sensitized with convertase either *in vivo* or *in vitro* by

immortalization of antibody-producing hybrid cell lines, thereby making available a permanent source of the desired antibody. In vivo immunization techniques are well known in the art, while in vitro techniques are generally described by Luben, R. and Mohler, M., 1980, Molecular Immunology, 17:635, Reading, C. Methods in
5 Enzymology, 121 (Part One):18, or Voss, B., 1986, Methods in Enzymology, 121:27. A number of in vitro immunization systems have been shown to be effective for sensitizing human B-cells. Reading, C., 1982, J. of Immun. Methods, 53:261.

It will be apparent to those skilled in the art, that in lieu of immunizing individuals directly with convertase, lymphocytes may be isolated from individuals that
10 are experiencing, or have experienced a bacteremic attack. A fraction of these lymphocytes will be sensitized to the convertase and can be used to produce permanent antibody secreting hybrid cell lines. For example, immunocompromised human patients are generally susceptible to bacterial infections, particularly those suffering from various malignancies, extensive burns, etc., and lymphocytes isolated therefrom
15 may be a source of antibody secreting cells.

Sensitized lymphocytes can be immortalized by viral transformation. The preferred viral transformation technique for human lymphocytes involves the use of Epstein-barr virus. The virus is capable of transforming human B-cells, and has been used to generate human monoclonal antibodies. Crawford, D. et al., 1983, J. of
20 General Virology, 64:697; Kozbor, V. and Roder, J., 1983, J. Immun. Today, 4:72.

Another procedure whereby sensitized lymphocytes may be immortalized consist of a combination of the above two techniques, that is viral transformation and cell fusion. The preferred combination consist of transforming antibody secreting cells with Epstein-barr virus, and subsequently fusing the transformed cells to a suitable
25 fusion partner. The fusion partner may be a mouse myeloma cell line, a heteromyeloma line, or a human myeloma line, or other immortalized cell line. PCT Patent Application No. 81/00957; Schlom et al., 1980, PNAS USA, 77:6841; Croce et al., 1980, Nature, 288:488. The preferred fusion partner is a mouse-human hetero-hybrid, and more preferred is the cell line designated F3B6. This cell line is on deposit with the
30 American Type Culture Collection, Accession No. HB8785. It was deposited April 18, 1985. The procedures for generating F3B6 are described in European Patent Application, Publication No. 174,204.

Techniques applicable to the use of Epstein-Barr virus transformation and the production of immortal antibody secreting cell lines are presented by Roder, J. et al.,
35 1986, Methods in Enzymology, 121:140. Basically, the procedure consist of isolating Epstein-Barr virus from a suitable source, generally an infected cell line, and exposing the target antibody secreting cells to supernatants containing the virus. The cells are

washed, and cultured in an appropriate cell culture medium. Subsequently, virally transformed cells present in the cell culture can be identified by the presence of the Epstein-Barr viral nuclear antigen, and transformed antibody secreting cells can be identified using standard methods known in the art.

5 It will be apparent to those skilled in the art that while the preferred embodiment of the instant invention is neutralizing anti-convertase monoclonal antibody, singly or in combination, that the antibody(s) may be altered and still maintain biological activity. Thus, encompassed within the scope of the invention is antibody modified by reduction to various size fragments, such as F(ab')₂, Fab, Fv, or
10 the like. Also, the hybrid cell lines that produce the antibody may be considered to be a source of the DNA that encodes the desired antibody, which may be isolated and transferred to cells by known genetic techniques to produce genetically engineered antibody. An example of the latter would be the production of single chain antibody having the antibody combining site of the hybridomas described herein. Single chain
15 antibody is described in U.S. Patent No. 4,704,692. A second example of genetically engineered antibody is recombinant, or chimeric antibody. Methods for producing recombinant antibody are shown in U.S. patent No. 4,816,567, inventor Cabilly, et al.; Japanese patent application, Serial No. 84169370, filed August 15, 1984; British patent application 8422238, filed on September 3, 1984; and Japanese patent
20 application, No. 85239543, filed October 28, 1985. Also, British patent application, No. 867679, filed March 27, 1986 describes methods for producing an altered antibody in which at least parts of the complementary determining regions (CDRs) in the light or heavy chain variable domains have been replaced by analogous parts of CDRs from an antibody of different specificity. Using the procedures described therein
25 it is feasible to construct recombinant antibody having the CDR region of one species grafted onto antibody from a second species that has its CDR region replaced. The preferred embodiment in this instance is a murine anti-convertase antibody CDR region that replaces the CDR region of human antibody.

In addition to antibody, compounds that compete with 26 kd TNF for binding
30 to the convertase will inhibit or reduce the conversion of 26 kd TNF to the 17 kd form, and thus be useful medicaments for treating sepsis. One such class of reagents consists of peptides or proteins, or other compounds synthetic, or naturally occurring, that have similar convertase binding activity as the 26 kd form of TNF. Preferred within this class are peptides or proteins that have amino acid sequences similar to that
35 found at the junction between 26 kd TNF and the 17 kd species. This sequence is Gln-Ala-Val-Arg-Ser-Ser-Ser, where Ala is the residue present on the portion of TNF remaining in the membrane after the cleavage event, and Val is the N-terminal amino

acid of 17 kd TNF. It is important to note that while the sequence is shown to consist of seven amino acids that what is minimally intended is a dipeptide sequence that is recognized by the convertase, and which is Ala-Val. Thus while the dipeptide sequence is required as part of an inhibitory peptide or protein, the latter may also have additional amino acids that enhance, or are even required, for the dipeptide sequence to bind to the convertase and inhibit its enzymatic activity.

An alternate embodiment of a peptide/protein convertase inhibitor is one that has the amino acid sequence, a sequence that is functionally similar to: Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala. This peptide spans both convertase cleavage sites, and thus would prevent the formation of the 17 kd form of TNF and lower molecular weight forms. The first, and dominant cleavage site is between alanine and valine at positions -1 and +1; and the second site is between proline and valine at positions +12 and +13. These positions correspond to the amino acid sequence shown in Figure 1.

A second class of competitive inhibitors consists of compounds having the sequence shown above, that is, Gln-Ala-Val-Arg-Ser-Ser-Ser, or Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala but wherein amino acids have been mutated or deleted to yield a non-cleavable substrate. A preferred embodiment of this peptide is a 26 kd non-cleavable TNF mutein produced by standard site specific mutagenesis techniques. Most preferred is a mutein wherein alanine and/or valine is substituted or deleted.

The peptides described above can be made by techniques well known in the art, such as, for example, the Merrifield solid-phase method described in Science, 232:341-347 (1985). The procedure may use commercially available synthesizers such as a Biosearch 9500 automated peptide machine, with cleavage of the blocked amino acids being achieved with hydrogen fluoride, and the peptides purified by preparative HPLC using a Waters Delta Prep 3000 instrument, on a 15-20 μ m Vydac C4 PrepPAK column.

Finally, it is important to be cognizant of the fact that the specificity of the convertase is similar to enzymes like elastase, that is, enzymes that cleave preferably between neutrally charged amino acids such as between valine, proline, and alanine residues. Thus, in addition to the peptide inhibitors mentioned above, a variety of other inhibitors known to inhibit elastase will also generally inhibit the enzyme that cleaves TNF. Using the assay described below, those compounds that inhibit the convertase can be identified. A variety of elastase inhibitors are commercially available, see for example, Boehringer Mannheim Biochemicals catalogues, or are known in the art.

Doherty, et al., 1986, Nature, 322:192; U.S. Patent Nos. 4,711,886; 4,797,396; 4,717,722; and 4,699,904. The preferred elastase inhibitors are modified cephalosporin antibiotics, such as those shown by Doherty, et al., above. More preferred is (1-((3-((acetyloxyl)-7-methoxy-8-oxy-8-oxo-5-thio-1-azabicyclo [4.2.0] oct-2-en-2-yl) carbonyl) morpholine, S,S-dioxide, (6R-cis). Also, Stetler, et al., 1986, Nucleic Acids Research, 14:7883, describe a cDNA clone that codes for an inhibitor of neutrophil elastase.

Most of the recombinant techniques that are described herein that may be used to transform cells, fabricate vectors, extract messenger RNA, and the like are widely practiced in biotechnology and most practitioners are familiar with the standard materials and methods employed. However, for convenience, the following paragraphs are offered as a guideline.

Construction of suitable vectors containing the desired TNF coding sequence employs standard ligation and restriction techniques which are well understood in the art. Isolated vectors, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and religated in the form desired.

Site specific DNA cleavage is performed by treating with suitable restriction enzyme(s) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes. See, e.g., New England Biolabs, Product Catalog. In general, about 1 µg of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 µl of buffer solution. In the examples herein, typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate. Incubation times of about one hour to two hours at about 37°C are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol followed by chromatography using a Sephadex G-50 spin column. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in Methods in Enzymology, 1980, 65:499-560.

Restriction cleaved fragments may be blunt ended by treating with the large fragment of *E. coli* DNA polymerase I, that is, the Klenow fragment, in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 minutes at 20 to 25°C in 50 mM Tris pH 7.6, 50 mM NaCl, 6 mM MgCl₂, 6 mM DTT and 10 mM dNTPs. After treatment with Klenow, the mixture is extracted with

phenol/chloroform and ethanol precipitated. Treatment under appropriate conditions with S1 nuclease results in hydrolysis of single-stranded portions.

Ligations are performed in 15-30 μ l volumes under the following standard conditions and temperatures: 20mM Tris-Cl pH 7.5, 10 mM $MgCl_2$, 10 mM DTT, 33 μ g/ml BSA, 10 mM-50 mM NaCl, and 1 mM ATP, 0.3-0.6 (Weiss) units T4 DNA ligase at 4°C for "sticky end" ligation, or for "blunt end" ligations. Intermolecular "sticky end" ligations are usually performed at 33-100 μ g/ml total DNA concentration. In blunt end ligations, the total DNA concentration of the ends is about 1 μ M.

In vector construction employing "vector fragments," the vector fragment is commonly treated with bacterial alkaline phosphatase (BAP) in order to remove the 5' phosphate and prevent religation of the vector. BAP digestions are conducted at pH 8 in approximately 150 mM Tris, in the presence of Na^+ and Mg^{+2} using about 1 unit of BAP per μ g of vector at 60°C for about 1 hour. Nucleic acid fragments are recovered by extracting the preparation with phenol/chloroform, followed by ethanol precipitation. Alternatively, religation can be prevented in vectors which have been double digested by additional restriction enzyme digestion of the unwanted fragments.

In the constructions set forth below, correct ligations are confirmed by first transforming the appropriate *E. coli* strain with the ligation mixture. Successful transformants are selected by resistance to ampicillin, tetracycline or other antibiotics, or using other markers depending on the mode of plasmid construction, as is understood in the art. Miniprep DNA can be prepared from the transformants by the method of D. Ish-Howowicz *et al.*, 1981, Nucleic Acids Res., 9:2989, and analyzed by restriction and/or sequenced by the dideoxy method of F. Sanger *et al.*, 1977, Proc. Natl. Acad. Sci. (USA), 74:5463 as further described by Messing *et al.*, 1981, Nucleic Acids Res., 9:309, or by the method of Maxam *et al.*, 1980 Methods in Enzymology, 65:499.

Host strains used in cloning in M13 consists of *E. coli* strains susceptible to phage infection, such as *E. coli* K12 strain DG98 are employed. The DG98 strain has been deposited with ATCC July 13, 1984 and has accession number 1965.

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. Calcium treatment employing calcium chloride, as described by S. N. Cohen, 1972 Proc. Natl. Acad. Sci. (USA) 69:2110, or the $RbCl_2$ method described by Maniatis *et al.*, 1984, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, p. 254, may be used for procaryotes. Transfection may also achieved using a modification of the calcium phosphate precipitation technique of Graham, F.L. *et al.*, 1973 Virology 52:456 or Wigler, *et al.*, 1978, Cell, 14:725.

Synthetic oligonucleotides were prepared by the triester method of Matteucci *et al.*, 1981, J. Am Chem. Soc. 103:3185 or using commercially available automated oligonucleotide synthesizers. Kinasing of single strands prior to annealing or for labeling is achieved using an excess, e.g., approximately 10 units of polynucleotide kinase to 0.1 nmole substrate in the presence of 50 mM Tris, pH 7.6, 10 mM MgCl₂, 5mM dithiothreitol, 1-2 mM ATP, 1.7 pmoles gamma ³²P-ATP (2.9 mCi/mmole), 0.1 mM spermidine, 0.1 mM EDTA.

Mutagenesis can be carried out using any number of procedures known in the art. These techniques are described by Smith, 1985, Annual Review of Genetics, 19:423, and modifications of some of the techniques are described in Methods in Enzymology, 154, part E, (eds.) Wu and Grossman (1987), chapters 17, 18, 19, and 20. The preferred procedure is a modification of the Gapped Duplex site-directed mutagenesis method. The general procedure is described by Kramer, *et al.*, in chapter 17 of the Methods in Enzymology, above.

Conventional M13 mutagenesis methods involve annealing a short synthetic oligonucleotide to single stranded M13 DNA having a cloned target coding sequence that is sought to be mutagenized. The oligonucleotide is almost, but not entirely complementary to the target sequence and has at least one mispaired nucleotide. After the annealing reaction, the remaining portion of the single stranded DNA must be filled in to give heteroduplex DNA that can be transfected into a suitable host cell which allows for the expression of the mutation. In the gapped duplex method, a partial DNA duplex is constructed that has only the target region exposed, unlike the conventional methods which have the target region and the rest of the single stranded M13 DNA exposed. Like the conventional methods, a short oligonucleotide is annealed to the target region, and extended and ligated to produce a heteroduplex. However, because only a small portion of single-stranded DNA is available for hybridization in the gapped duplex method, the oligonucleotide does not anneal to undesired sites within the M13 genome. Further, this method has the additional advantage of introducing fewer errors during the formation of the heteroduplex since only a very small region of DNA on either side of the target region has to be filled in.

More specifically, the gapped duplex method involves cloning the target DNA sequence into an appropriate M13 phage that carries selectable markers, such as for example the stop codon amber mutation. The latter allows for negative selection in a host cell that cannot suppress the effects of the mutation. Preferably the phage is M13mp9 which contains two amber codons in critical phage genes. Thus, the sequence that encodes 26 kd TNF is cloned into M13mp9 amber+, and single stranded DNA is prepared therefrom using standard techniques. Next, double stranded

replicative form DNA from M13 GAP, a genetically engineered M13 derivative that lacks the amber codons is cleaved with Hinc II restriction enzyme. The base sequence of M13 GAP is similar to M13mp18, which lacks both the amber codons and the sequence between base pairs 6172 and 6323. This deletion flanks the multiple cloning sites of the M13mp series and generates a unique Hinc II site. Gapped duplex DNA is formed, using standard DNA/DNA hybridization techniques, consisting of single stranded DNA having the amber codons, and a second strand of DNA from Hinc II digested M13 GAP lacking both the amber codons and the TNF coding sequences. Thus, the only portion of the gapped duplex that is exposed is the 26 kd TNF target sequence. The desired oligonucleotide is annealed to the gapped duplex DNA, and any remaining gaps filled in with DNA polymerase and the nicks sealed with DNA ligase to produce a heteroduplex. The latter is transfected, preferably into a mismatch repair deficient host, and mixed phage produced. From the mixed phage population, phage carrying unmutated 26kd TNF DNA, which also have the amber mutations, can be selected against by infecting the mixed phage population into a host cell that cannot suppress the amber mutation. Clones can then be screened for phage that carry the desired TNF mutation.

Compounds identified as having convertase inhibitory activity will also have prophylactic or therapeutic applications in the treatment of sepsis. Because the onset of sepsis is associated with an increase in circulating TNF, these inhibitors may be used prophylactically in those instances where there is a risk of bacterial infection, particularly in a pre-operative setting. Similarly in those instances where there is an early diagnosis of sepsis, the inhibitors will have beneficial therapeutic effects in substantially reducing the amount of TNF that is produced.

A second medical application for inhibitors of convertase is for the treatment of AIDS. It has been shown that TNF causes the activation of latent human immunodeficiency virus. Folks *et al.*, Proc. Natl. Acad. Sci. USA, vol. 86, p. 2365 (1989). Thus, preventing or inhibiting the formation of the 17 kd, or lower molecular weight forms of TNF by inhibition of the convertase would be a valuable prophylactic for the treatment of AIDS, and would preferable be used to treat patients that are infected with the virus that is in a latent phase.

Having generally described what the applicants believe their invention to be, presented below are examples that are illustrative of the scope of the invention. It will be appreciated by those skilled in the art that the examples are not intended to be construed as limiting the invention to the materials and methods shown as there are numerous substitutions that can be made therein without departing from the scope of the invention.

Example 1

Conversion of 26 kd TNF

The vector pFVXM, on deposit with the American Type Culture Collection, Accession No. 67,103, was used to produce a vector pFVXM-TNF6, which contains
5 the DNA sequence that encodes the 26 kd TNF species. To produce the latter vector, the plasmid B11 which contains the cDNA sequence that encodes the 26 kd TNF species was treated with Pst I which excises the coding sequence. The fragment was purified using standard electrophoretic techniques. Next, the vector pFVXM was treated with Pst I, and the Pst I fragment from pB11 containing the 26 kd coding
10 sequence was inserted into the polylinker region of the vector using standard techniques, as described above, to produce pFVX-TNF6. pFVX-TNF6 was used to produce the cell line TNF 6.8, as described by Kriegler et al, (1988), above, or as described in U.S. patent application titled "Cleavage Site Blocking Antibody to Prohormone Proteins and Uses Thereof," filed on the same day as the instant patent
15 application. This application is Cetus Case No. 2534, inventors Kriegler and Perez.

TNF 6.8 expresses both 26 kd and 17 kd TNF. Figure 2 shows the conversion of 26 kd TNF by convertase activity present in HL 60 cells. The production of labelled 26 kd TNF by in vitro transcription/translation, and analysis by gel electrophoresis is described below, in Example 2. Note that the S-1 cytosol or
20 pellet fractions cause the near complete conversion of 26 kd TNF to a 17 kd species. Figure 2 also shows, for comparative purposes, 26 kd and 17 kd TNF in a lysate of TNF 6.8 cells.

pFVXM and the plasmid pB11 were both amplified in E. coli strain HB101. Ligation of the fragments was carried out using standard conditions. Plasmid DNA was
25 isolated after the ligation procedure and the correct orientation of the TNF encoding sequences was established by restriction analysis.

Plasmid DNA was prepared according to the procedure of Birnboim and Doly, as described in Nucleic Acid Research, 7:1513 (1979). The plasmid DNA was banded twice in cesium chloride, and exhaustively dialyzed against TE buffer consisting of 10
30 mM Tris, pH 8.0, and 1 mM EDTA.

Example 2

Convertase Assay

A. In Vitro Transcription/Translation Assay

The preferred assay procedure consists of in vitro transcription/translation of the
35 26 kd molecule, followed by treatment with convertase in the presence or absence of compounds being tested for convertase inhibitory activity. The procedure entails in

in vitro transcription/translation of the 26 kd molecule present in the plasmid B11. Thus, the sequence is removed from pB11 by Pst I digestion and inserted into the Pst I site of pGEM-3 (obtainable from Promega Biotec). The resulting plasmid, termed pGEM-TNF14, was amplified in *E. coli* using established techniques, and plasmid DNA prepared according to the procedure of Birnboim and Doly, described above. Plasmid DNA was in vitro transcribed by linearizing it with Hind III, and the linearized plasmid templates used to prepare capped transcripts with T7 RNA polymerase and an in vitro transcription kit supplied by Promega Biotec. Transcription was performed using standard techniques as suggested by the manufacturer's instructions.

The mRNA was in vitro translated in the presence of ³⁵S-cysteine to produce ³⁵S-cysteine labelled 26 kd TNF. The procedure consisted of using a rabbit reticulocyte lysate translation kit, also supplied by Promega Biotec, and following the conditions recommended by the manufacturer.

³⁵S-cysteine labelled 26 kd TNF was used to assay for convertase inhibitors as follows. 25 µl of in vitro translated material was combined with 250 µl of uninduced HL60 convertase activity, plus compounds sought to be assayed for inhibitory activity. The convertase was produced by harvesting 2 x 10⁹ HL60 cells, and isolating S-1 and P-30 fractions totalling 18 and 6 ml, respectively. 250 λ of the P-30 fraction was used, although the S-1 fraction may also be used. The assay was carried out at 30°C for 1 hour, essentially as described above. Next, the reaction mixture was immunoprecipitated with anti-TNF polyclonal antisera and protein A sepharose, pelleted and washed. The bound protein was eluted and electrophoresed. The gel was dried and exposed to x-ray film and subsequently developed. The gel electrophoretic profiles of 26 kd TNF treated with varying dilutions of HL60 convertase revealed those compounds with inhibitory activity.

Using the above assay, it was determined that 3,4-dichloro-isocoumarin and elastinal at concentrations of 100 µg/ml and 5 mg/ml, respectively, inhibit the convertase. It was also shown that 1-((3-((acetyloxyl)-7-methoxy-8-oxy-8-oxo-5-thio-1-azabicyclo [4.2.0] oct-2-en- 2-yl) carbonyl) morpholine, S,S-dioxide, (6R-cis) at a concentration of 1 mM inhibits convertase activity. These results are shown in figure 3.

B. Monocyte Assay

In addition to 26 kd TNF produced by the in vitro transcription/translation assay described above, stimulated monocytes which produce 26 kd TNF, as described by Kriegler, *et al.*, 1988, Cell, 53:45, and thus may be used as a source of the molecule.

A suitable assay procedure is to stimulate monocytes, and then in the presence of the convertase, measure the disappearance of the 26 kd species to a lower molecular weight species, preferable 17 kd TNF.

5 Briefly, human monocytes are purified from human blood by centrifugation, and subsequently enriched for based on the adherence of monocytes to cell culture dishes. Centrifugation consist of purifying the monocytes through Ficoll-plaque and percoll (49.2%), obtainable from Pharmacia. The manufacturers recommended procedures are followed. Next, the mixture of cells resulting from the centrifugation step, consisting of monocytes and lymphocytes, are plated onto tissue culture dishes
10 containing RPMI media supplemented with 20% fetal calf serum. The dishes are incubated for 30 minutes at 37°C after which they are extensively rinsed with the same media. This treatment removes non-adherent lymphocytes and leaves remaining only adherent monocytes.

Monocyte 26 kd TNF is radiolabelled as follows. The monocytes are incubated
15 for 3 hours at 37°C in RPMI media supplemented with 20% fetal calf serum, 100 ng/ml lipopolysaccharide, and 10 µg/ml phorbol myristate acetate for 30 minutes at 37°C. The latter two compounds induce the expression of TNF. The RPMI media is cysteine-minus, and the fetal calf serum present at a final concentration of 5%. The serum is dialyzed prior to use to remove any cysteine present. After the 30 minute incubation
20 period, 100 uCi ³⁵S-cysteine is added and the cells are radiolabelled for 3 hours at 37°C after which they are lysed and used to assay for convertase activity. The steps for carrying out the assay, as well as identifying inhibitors of the convertase, are similar to those described above.

Example 3

25 TNF Mutein/Antibody/Peptide Inhibitors of Convertase Activity

The following compounds will have convertase inhibitory activity and can be prepared as follows, and tested for inhibitory activity as described above.

A. Anti-Convertase Antibody

Antibody, either monoclonal or polyclonal, is prepared that either neutralizes the
30 enzymatic activity of the convertase, or that binds to the convertase and thereby sterically prevents the convertase from binding to 26 kd TNF. The procedure consists of immunizing an appropriate host animal with a membranous fraction of HL60 cells producing the convertase. A sufficient amount of material should be used to elicit an immune response, and usually this will consist of between 10 µg to 10 mg per
35 kilogram of body weight. Immunization may be conducted with adjuvant in a

biologically acceptable buffer, as is known in the art. The best immunization route can be determined experimentally, and the primary immunization may be followed by one or more secondary immunizations depending on the strength of the immune response to the initial immunization. The presence of neutralizing anti-convertase antibody in the sera may be detected using the convertase assay described above wherein antisera is present in the assay mixture. Inhibition of the conversion of the 26 kd TNF species to a lower molecular weight species indicates the presence of neutralizing antibody. It is, of course, assumed that the proper controls are conducted to insure that anti-sera from non-immunized animals is not inhibitory. Polyclonal antibody may be purified as described below.

Monoclonal antibody to the convertase may be produced using either *in vivo* or *in vitro* immunization techniques, and sensitized lymphocytes resulting therefrom can be used to prepare hybrid cell lines that secrete the appropriate monoclonal antibody. Rodent, preferably of murine origin, or human antibody is most preferred. The *in vivo* immunization procedure involves sensitizing lymphocytes to the convertase by immunizing either mice or humans, and isolating therefrom the antibody secreting cell fraction and immortalizing the cells therein by one of several procedures. An alternate embodiment is to isolate lymphocytes that have already been sensitized to the convertase from septic patients, as described above.

(i) Murine Antibody

For *in vivo* immunization of mice, the procedure of Kohler and Milstein described in Nature, 256:495 (1975) may be followed, or modified procedures such as those shown by Fendly, et al., 1987, Hybridoma, 6:359; Buck, et al., 1988, In Vitro, 18:377. *In vitro* techniques are generally described by Luben, R. and Mohler, M., 1980, Molecular Immunology, 17:635, Reading, C. Methods in Enzymology, 121 (Part One):18, or Voss, B., 1986, Methods in Enzymology, 121:27.

Mice are immunized with 1 mg/ml of a membranous fraction of HL-60 cells previously shown to be positive for convertase activity. The immunization is carried out in complete Freund's adjuvant. Two additional immunizations, or boosts, are performed at monthly intervals without adjuvant, and one month after the last boost the mice are given an I.V. boost of 10 ug of membranous material. Three days after the I.V. boost, mice are sacrificed, their spleens removed, and the spleenocytes isolated and fused to an immortalized drug selectable myeloma partner cell line. Numerous such myeloma lines are known in the art, most of which are incapable of growth in HAT supplemented cell culture media. A typical myeloma cell line is SP-2/OAg 14. Thus, the hybridomas are formed by combining splenocytes and myeloma cells in a 5:1

ratio, which generally consists of 2×10^6 myeloma cells to 1×10^7 splenocytes. The cell mixture is pelleted, media removed and fusion affected by the addition of 1.0 ml of 40% (v/v) solution of polyethylene glycol 1500 by dropwise addition over 60 seconds at room temperature, followed by a 60 second incubation at 37°C . To the cell suspension with gentle agitation is added 9 ml of Dulbecco's Modified Eagles medium over 5 minutes. Cell clumps in the mixture are gently resuspended, the cells washed to remove any residual PEG and plated in microtiter plates at about 2×10^5 cells/well in DMEM supplemented with 20% fetal calf serum. After 24 hours, the cells are fed a $2 \times$ solution of hypoxanthine and azaserine selection medium.

Media from wells that exhibit positive cell growth may be screened for neutralizing monoclonal antibody to the convertase. The preferred assay is the convertase assay described in Example 2, above, wherein media sought to be tested for antibody activity is present in the assay. More preferred is to combine culture supernatants from 3-8 microtiter wells, and assay the mixture. If the mixture is positive, then media from each well may be assayed independently to identify the secreting hybridoma(s). Many assays are known in the art and can detect soluble, or non-soluble antigens, and are shown by Langone, J. and Van Vinakis, H., Methods of Enzymology, 92, Part E (1983).

Regardless of whether the antibody is polyclonal or monoclonal it is desirable to purify the antibody by standard techniques as is known in the art, or described by Springer, 1980, Monoclonal Antibodies, 194, (Eds. Kennett, T. McKearn and K. Bechtol, Plenum Press, New York. Generally this consists of at least one ammonium sulfate precipitation of the antibody using a 50% ammonium sulfate solution. Antibody affinity columns may also be used.

(ii) Human Monoclonal Antibody

Peripheral blood lymphocytes are isolated from septic patients, and then infected with Epstein-Barr virus and the infected lymphocytes immortalized by fusion to a selectable myeloma cell line, and the hybrid cell lines so generated isolated and characterized as to antibody production.

More specifically, mononuclear cells are separated on Ficoll-hypaque (Pharmacia), and monocytes depleted from the mixture by adherence to plastic. Standard laboratory techniques were utilized to effect these procedures. Next, nonadherent cells are enriched for antibody producers by antigen-specific panning. Panning is a technique generally known in the art, and involves incubation of a population of antibody secreting cells on a plastic surface coated with the appropriate antigen. Those cells that express antibody on their surface bind antigen, and

consequently adhere to the plastic surface, whereas cells that do not express cell surface antibody, do not adhere and can be removed by washing. Thus, specific antibody secreting cells are enriched for by this technique.

More specifically, 6-well plates (Costar) are coated with a membrane fraction
5 containing convertase prepared from either induced or uninduced HL60 cells, as described above, such that 150 μ g of membranous material is coated per well in phosphate buffered saline at 4°C overnight. The wells are blocked after the overnight incubation period with phosphate buffered saline containing 1% bovine serum albumin for at least 1 hour at 4°C, and subsequently washed with phosphate buffered
10 saline/BSA. Next, 10⁷ lymphocytes in 1 ml of PBS/BSA are added to each well of the six well plates. The lymphocytes are allowed to incubate on the plates for 70 minutes, after which any nonadherent cells are removed by aspiration. The adherent cells are incubated with cell culture medium (IMDM, Sigma Chemical Co., St. Louis, Missouri) containing 10% fetal calf serum.

15 The adherent cells are subjected to Epstein-Barr virus transformation by adding an equal amount of culture media obtained from growing the Epstein-Barr virus infected marmoset cell line, B95-8, and thus containing the virus, to media bathing the adherent cells. The cells were cultured in this environment at 37°C for 3 hours, and in this way the lymphocytes in the adherent cell population are subjected to Epstein-Barr
20 infection. Following the infection period, the cells are washed and plated onto 96 well microtitre plates at a density of about 10⁴ - 10⁵ cells/well in IMDM medium, plus 10% fetal calf serum, and 30% conditioned medium. The latter is derived from a lymphoblastoid cell line, preferably JW5. The medium also contains 5 x 10⁻⁵ M 2-mercaptoethanol, 50 μ g/ml gentamycin sulfate (Sigma), and 600 ng/ml cyclosporine A
25 (Sandimmun, Sandoz, Basel, Switzerland).

After about 14 to 21 days of incubation, cell culture supernatants are combined and screened for convertase neutralizing activity as described above. Positive
hybridomas are subcultured at low density, retested for neutralizing antibody, and grown up and fused to the cell line F3B6 using polyethylene glycol and the plate fusion
30 technique known in the art. The latter technique is described by Larrick, J.W., (1985) in Human Hybridomas and Monoclonal Antibodies, E.G. Engleman, S.K.H. Fong, J.W., Larrick, and A.A. Raubitschek, Editors, Plenum Press, New York, page 446. F3B6 is a heteromyeloma cell line that is sensitive to growth in media containing 100 μ M hypoxanthine, 5 μ g/ml azaserine and 5 μ M ouabain. Finally, the resulting hybrids
35 are again screened to insure that they produce neutralizing anti-convertase antibody.

B. 26 kd Non-Cleavable Muteins

26 kd TNF muteins are described that compete for binding to the convertase, thereby inhibiting or reducing its activity. The preferred embodiment muteins are those having valine at positions 1 and/or 13; or alanine at position -1 and/or proline at position 12, replaced/ or deleted. The muteins are constructed using a modification of the site directed mutagenesis gapped duplex method.

The following solutions/buffers are used to perform the desired procedures:

5 x Gapped duplex buffer (GDB) consisting of 0.938 M KCl, 0.063 M Tris, pH 7.5; 10 x PEL consisting of 1.0 M KCl, 0.30 M Tris, 0.15 M MgCl₂, 0.02 M DTT, pH 7.5; 10 x KB consisting of 0.50 M Tris, 0.10 M MgCl₂, 0.05 M DTT, 0.001 M EDTA, pH 8.0; a solution containing 0.25 mM dCTP, dATP, dGTP, dTTP, made fresh from 10 mM stocks; an ATP solution consisting of 0.1 M ATP made by dissolving 60 mg of ATP in 0.80 ml of H₂O and adjusting the pH to 7.0 with 0.1 M NaOH in a final volume of 1.0 ml with H₂O; 20% PEG/2.5 M NaCl; 3.0 M NaOAc; and TE Saturated Phenol.

Various bacterial strains and phage are employed to yield the desired muteins and these are BMH 71-18, JM103 for growing phage strains; HB2154: MutL, Su⁻, made competent for DNA transformation; and HB2151: Su⁻, used as lawn cells during transformation; M13 GAP, the RF is used for the formation of the gapped duplex; and M13mp19amber, the 26 kd TNF target DNA is cloned in this vector, and ssDNA isolated for the formation of gapped duplex.

Phage are infected into an appropriate bacterial strain, grown up, and titered as follows. In making a large-scale preparation of either phage for ssDNA or cells for dsDNA, or RF DNA, the same infection protocol is used.

Plaque purified phage is produced using standard techniques. Briefly, this consists of streaking phage supernatants on agar plates, followed by careful overlay with 4.0 ml of soft agar and 100 µl of fresh overnight culture of BMH 71-18. Next, isolated plaques are picked and incubated with a 1:50 dilution of fresh overnight culture of BMH 71-18 in R26 or R17 + 10 mM MgCl₂ with shaking at 37°C for 4.5-6 hours. R17 (N-Z amine broth) consist of 10 g N-Z amine, type A, 5 g NaCl with H₂O to 1 liter, while R26 consist of 8 g tryptone, 5 g yeast extract, 5 g NaCl, with water to 1 liter (YT broth). The phage stock is titered, and phage infected into bacteria at a multiplicity of infection (MOI) of 10. After incubating the culture with shaking at 37°C for 5 hours the cell suspension is pelleted, and the supernatant saved for ssDNA isolation, and the cells for RF isolation. RF DNA is isolated using established plasmid DNA isolation techniques, while ssDNA is isolated as follows.

250 ml of phage supernatant is spun down hard, after which 200 ml of the supernatant is decanted, followed by adding 50 ml of 20% PEG/2.5 M NaCl, and incubation overnight at 4°C, or on ice for 30 minutes. This mixture is also spun down hard, and the supernatant decanted. The bottle is spun again to pellet the phage precipitate along the sides of the bottle, and the remaining fluid aspirated with a Pasteur pipette. The pellet is resuspended in 5.0 ml of 1 x TE, and stored at 4°C, after which 0.5 ml of is extracted twice with 0.5 ml of TE saturated phenol. To the aqueous layer is added 0.050 ml of 3.0 M NaOAc and 1.0 ml 95% ethanol. The mixture is placed in a dry ice bath for 10 minutes, and centrifuged for 10 minutes in a microfuge at 4°C. The pellet is dried, and resuspended in 200 µl of 1X TE. This material may be stored in 0.050 ml aliquots at -20°C until used in the mutagenesis of 26 kd TNF.

The following oligonucleotides are used to change valine at positions 2 and/or 13, alanine at position -1 and proline at position 12. The oligonucleotides and their corresponding muteins are shown in Table 1.

Table 1

15	1. <u>Muteins</u>
	(a) <u>Deletions</u>
	ΔVAL 1
	ΔVAL 13
	ΔVAL 1 + ΔPRO 12
20	ΔVAL 1 + ΔVAL 13
	(b) <u>Substitutions</u>
	(VAL 1 → ALA 1) + (VAL 13 → ALA 13)
	(VAL 1 → GLY 1) + (VAL 13 → GLY 13)
	(VAL 1 → LEU 1) + (VAL 13 → LEU 13)
25	(VAL 1 → MET 1) + (VAL 13 → MET 13)
	(VAL 1 → PHE 1) + (VAL 13 → PHE 13)
	(VAL 1 → HIS 1) + (VAL 13 → HIS 13)
	(VAL 1 → THR 1) + (VAL 13 → THR 13)
	(ALA 1, VAL 1 → GLN 1, HIS 1) + (PRO 12, VAL 13 → GLN 12, HIS 13)
30	(ALA 1, VAL 1 → GLN 1, HIS 1) + (PRO 12, VAL 13 → SER 12, THR 13)

2. Oligonucleotides

- CP 495 : ΔVAL 1
5'- TCG AGA AGA TGA TCT TGC CTG GGC CAG AGG -3'
CP 496 : screens ΔVAL 1
5'- TGA TCT TGC CTG -3'
- CP 497 : ΔPRO 12
5'- TAC AAC ATG GGC TAC CTT GTC ACT CGG GGT-3'
CP 498 : screens ΔPRO 12
5'- GGC TAC CTT GTC -3'
- CP 499 : ΔVAL 13
5'- TGC TAC AAC ATG GGC AGG CTT GTC ACT CGG -3'
CP 500 : screens ΔVAL 13
5'- ATG GGC AGG CTT -3'
- CP 501 : VAL-1 → ALA 1
5'- TCG AGA AGA TGA TCT AGC TGC CTG GGC CAG AGG -3'
CP 502 : screens VAL 1 → ALA 1
5'- GAT CTA GCT GCC -3'
- CP 503 : VAL 13 → ALA 13
5'- TGC TAC AAC ATG GGC AGC AGG CTT GTC ACT CGG -3'
- CP 504 : screen VAL 13 → ALA 13
5' TGG GCA GCA GGC -3'
- CP 505 : VAL 1 → GLY 1
5'- TCG AGA AGA TGA TCT ACC TGC CTG GGC CAG AGG -3'
CP 506 : screens VAL 1 → GLY 1
5'- GAT CTA CCT GCC -3'
- CP 507 : VAL 13 → GLY 13
5'- TGC TAC AAC ATG GGC ACC AGG CTT GTC ACT CGG -3'
- CP 508 : screens VAL 13 → GLY 13
5'- TGG GCA CCA GGC -3'
- CP 509: VAL 1 → LEU 1
5'- TCG AGA AGA TGA TCT CAG TGC CTG GGC CAG AGG -3'
CP 510 : screens VAL 1 → LEU 1
5'- GAT CTC AGT GCC T-3'
- CP 511 : VAL 13 → LEU 13
5'- TGC TAC AAC ATG GGC CAG AGG CTT GTC ACT CGG -3'
- CP 512 : screens VAL 13 → LEU 13
5'- TGG GCC AGA GGC T-3'

CP 513 : VAL 1 → MET 1

5'- TCG AGA AGA TGA TCT CAT TGC CTG GGC CAG AGG -3'

CP 514 : screens VAL 1 → MET 1

5'- GAT CTC ATT GCC T-3'

5 CP 515 : VAL 13 → MET 13

5'- TGC TAC AAC ATG GGC CAT AGG CTT GTC ACT CGG -3'

CP 516 : screens VAL 13 → MET 13

5'- TGG GCC ATA GGC T-3'

CP 517 : VAL 1 → PHE 1

10 5'- TCG AGA AGA TGA TCT AAA TGC CTG GGC CAG AGG -3'

CP 518 : screens VAL 1 → PHE 1

5'- GAT CTA AAT GCC T-3'

CP 519 : VAL 13 → PHE 13

5'-TGC TAC AAC ATG GGC AAA AGG CTT GTC ACT CGG -3'

15 CP 520 : screens VAL 13 → PHE 13

5'- TGG GCA AAA GGC T-3'

CP 521 : VAL 1 → HIS 1

5'- TCG AGA AGA TGA TCT ATG TGC CTG GGC CAG AGG -3'

CP 522 : screens VAL 1 → HIS 1

20 5'- GAT CTA TGT GCC T-3'

CP 523 : VAL 13 → HIS 13

5'- TGC TAC AAC ATG GGC ATG AGG CTT GTC ACT CGG -3'

CP 524 : screens VAL 13 → HIS 3

5'- TGG GCA TGA GGC T-3'

25 CP 525 : VAL 1 → THR 1

5'- TCG AGA AGA TGA TCT AGT TGC CTG GGC CAG AGG -3'

CP 526 : screens VAL 1 → THR 1

5'- GAT CTA GTT GCC T-3'

CP 527: VAL 13 → THR 13

30 5'- TGCTAC AAC ATG GGC AGT AGG CTT GTC ACT CGG -3'

CP 528 : screens VAL 13 → THR 13

5'- TGG GCA GTA GGC T-3'

CP 529 : ALA 1, VAL 1 → GLN 1, HIS 1

5'- TCG AGA AGA TGA TCT ATG CTG CTG GGC CAG AGG GCT -3'

35 CP 530 : screens ALA 1, VAL 1 → GLN 1, HIS 1

5'- TCT ATG CTG CTG -3'

CP 531 : PRO 12, VAL 13 → GLN 12, HIS 13

5' TGC TAC AAC ATG GGC ATG CTG CTT GTC ACT CGG GGT -3'

CP 532 : screens PRO 12, VAL 13 → GLN 12, HIS 13

5' GGC ATG CTG CTT -3'

5 CP 533 : PRO 12, VAL 13 → SER 12, THR 13

5' TGC TAC AAC ATG GGC AGT GCT CTT GTC ACT CGG GGT -3'

CP 534 : screens PRO 12, VAL 13 → SER 12, THR 13

5' GGC AGT GCT CTT -3'

The oligonucleotides are kinased using the following reaction solution and
 10 conditions: 3 μ l 10 x KB buffer, 3 λ 10 mM rATP (1:10 dilution of 0.1 M rATP stock), 2 λ mutagenic oligonucleotide (100 pmole/ λ), 21 λ H₂O, and 1 λ polynucleotide kinase (10 units/ λ). The reaction is run at 37°C for 45 minutes, and then at 65-68°C for 5 minutes. Next, 24 λ of the kinased oligonucleotide is diluted with 56 λ of H₂O to give 2 pmole/ λ .

15 The gapped duplex is formed as described below, followed by annealing the oligonucleotides. The following reagents are combined in a total volume of 40 λ : 8 λ 5 x GDB buffer, 0.50 pmole ssDNA, and 0.10 pmole Hinc II linearized M13 GAP RF DNA. 10 λ is removed for future use, and the remaining 30 λ is treated sequentially as follows: 100°C for 3 minutes, 65°C for 5 minutes, followed by cooling to room
 20 temperature for 30 minutes, and then placing the reaction mixture on ice. Next, 10 λ of gapped duplex and 10 λ of control ungapped material is subject to electrophoresis on a agarose gel to check gapped duplex formation. Assuming the gel shows the presence of a third band, the gapped duplex has formed and the kinased oligonucleotides can be annealed to the duplex by combining 16 λ of gapped duplex reaction mixture, and 4 λ
 25 of diluted kinased oligonucleotide, and heating the mixture to 65°C for 3 minutes, followed by cooling to room temperature for 20 minutes.

The heteroduplex is completed by the appropriate extension and ligation reactions consisting of combining the following reagents in a total volume of 40 λ : 10 λ gapped duplex and primer, 4 λ 10 x PEL buffer, 4 λ dNTP's (0.25 mM solution
 30 made from 10 mM stocks, 3 λ ATP (10 λ of 0.1 M ATP stock + 1490 λ H₂O = 0.662 mM), 17 λ H₂O, 1 λ Klenow (5 u/ λ), and 1 λ T4 DNA ligase (0.6 Weiss u/ λ , diluted

stock with 1 x PEL). The reaction is conducted at 16°C for 2 hours, followed by transformation of 10 λ of the extension/ligation mixture into 200 λ of thawed competent HB2154 cells. The cells are kept at 0°C for 30 minutes, and then 42°C for 1.5 minutes, followed by plating various volumes of the transformation mix (e.g., 50 λ , 10 λ , etc.) with 100 λ of fresh overnight culture of HB2151 cells + 3.0 λ of soft agar.

The resulting plaques are screened using the plaque hybridization procedure. While a variety of such procedures are known, a description of the preferred procedure follows. Plates are replicated onto duplicate nitrocellulose filter papers (S & S type BA-85) and the DNA fixed to the filter by sequential treatment for 5 minutes with 0.5 N NaOH plus 1.5 M NaCl; 1.0 M NaCl plus 0.5 M Tris-HCl pH 7.4; and 2 x SSC (standard saline citrate). Filters are air dried and baked at 80°C for 2 hours, *in vacuo*.

The duplicate filters are prehybridized at 55°C for 2 hours with 10 ml per filter of DNA hybridization buffer, 5 x SSC, pH 7.0, 5 x Denhardt's solution (polyvinylpyrrolidone, plus Ficoll and bovine serum albumin; 1 x 0.02% of each), 50 mM sodium phosphate buffer at pH 7.0, 5 mM EDTA, 0.1% SDS, and 100 μ g/ml yeast RNA. The prehybridization buffer is removed and the samples hybridized with the appropriate kinased probe, that is to say kinased oligonucleotides as shown above, under conditions which depend on the stringency desired. About 2 x 10⁶ cpm/ml total is used. Typical moderately stringent conditions employ a temperature of 42°C plus 50% formamide for 24-36 hours with 1-5 ml/filter of DNA hybridization buffer containing probe. For higher stringencies high temperatures and shorter times are employed. The preferred hybridization conditions consists of hybridizing the probes to the filters in 5 x SSC, Denhardt's solution, 50 mM NaPO₄, pH 7.0, 5 mM EDTA, 0.1% SDS, and 100 mg/ml yeast RNA at 10° below the T_M of the oligonucleotide used to do the screening. Next, the filters are washed twice, 30 minutes each wash, at room temperature with 2 x SSC, 0.1% SDS, then washed once with 2 x SSC and 0.1% SDS at 5°C below the T_M of the oligonucleotide used to screen, and air dried. Finally, the filters are autoradiographed at -70°C for 36 hours. Autoradiography reveals those plaques containing the virus that carries the muteins of interest.

In addition to constructing muteins wherein valine at position 2 and/or 13 have been deleted or substituted, large deletion muteins may be produced that encompass the two predominate cleavage sites of 26 kd TNF. A preferred embodiment mutein lacks the amino acids spanning the region -9 to +14, as shown in Figure 1. This mutein was

constructed using the materials and methods described above and the oligonucleotide, CP375 which has the following sequence:

5'-GTTTGCTACAACATGGAGGTCCTGGGGGA-3'

C. Protein/Peptide Inhibitors

5 Peptides having the following amino acid sequences are synthesized by the solid-phase method, described in detail by Merrifield, R.B (1985) in *Science*, 232:341-347: Gln-Ala-Val-Arg-Ser-Ser-Ser; Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala; Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala-His-Val-Val-Ala; Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala-His-Val-Val-Ala; and Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro. A
10 Biosearch 9500 automated peptide machine is used with hydrogen fluoride cleavage, and purification by preparative HPLC using a Waters Delta Prep 3000 instrument, on a 15-20 μ m Vydac C4 PrepPAK column.

That these peptides inhibit convertase activity is shown by performing the assay
15 described above in the presence of varying amounts of each peptide. Gel electrophoresis and western blotting of the reaction mixture shows an inhibition of conversion of the 26 kd TNF to the 17 kd form.

Example 4

Protective Effect of Convertase Inhibitors in the Treatment of Sepsis

20 Compounds that are effective inhibitors of convertase activity are shown to prevent sepsis in a baboon model system as follows. Anti-convertase antibody, murine, human, or recombinant, at a concentration of 5 mg/kg is administered in a single I.V. bolus 60 minutes before the animals are challenged with a lethal dose of *E. coli*, and 2 mg/kg simultaneously with the *E. coli* challenge. The antibody is
25 administered in a physiologically balanced salt solution, and about 4×10^{10} *E. coli* organisms are used. The *E. coli* dose is infused over a two hour period. Animals that receive the antibody are protected for at least 7 days, whereas control animals that are administered only the balanced salt solution expire within 16 to 32 hours.

Similar protection is attributable to the TNF mutein convertase inhibitors shown
30 in Example 3. The muteins are administered at a concentration of 5 mg/kg in a single I.V. bolus 60 minutes before the animals are challenged with 4×10^{10} *E. coli* organisms. The baboons also receive 2 mg/kg of the muteins simultaneously with the *E. coli* challenge.

Finally, the peptides shown in Example 3, that is, Gln-Ala-Val-Arg-Ser-Ser-Ser and, Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala are tested as described above and yield similar protective effects.

5 The present invention has been described with reference to specific embodiments. However, this application is intended to cover those changes and substitutions which may be made by those skilled in the art without departing from the spirit and the scope of the appended claims.

WE CLAIM:

1. A method for identifying prophylactics or therapeutics of diseases caused by a mature protein hormone, or one or more lower molecular weight species of said mature protein hormone, that are produced from a prohormone by convertase cleavage of said prohormone, comprising the steps of:
 - a) Contacting said prohormone with an effective amount of said convertase;
 - b) Measuring the conversion of said prohormone to said mature hormone or one or more lower molecular weight species of said mature hormone;
 - c) Repeating steps "a" and "b" above, and further including a molecule sought to be identified as a prophylactic or therapeutic of diseases caused by said mature hormone ;
 - d) Measuring the conversion of said prohormone to said mature hormone or lower molecular weight species of said mature hormone; and
 - e) Comparing the amount of conversion of said prohormone from steps "b" and "d"
2. Therapeutics or prophylactics for treating diseases caused by mature protein hormones identified by the method of claim 1.
3. Therapeutics or prophylactics for treating diseases caused by mature protein hormones that are produced from prohormones by convertase cleavage, said therapeutics or prophylactics having the property of inhibiting or preventing said convertase from producing said mature hormone by competing with said convertase for binding to said prohormone.
4. A method as described in claim 1, wherein said prohormone is 26 kd TNF.
5. A method of identifying prophylactics or therapeutics of sepsis, comprising the steps of:
 - a) Contacting TNF having a molecular weight of about 26,000 with an effective amount of TNF convertase;
 - b) Measuring the conversion of TNF having a molecular weight of about 26,000 to one or more lower molecular weight TNF species;

- c) Repeating steps "a" and "b" above, and further including a molecule sought to be identified as a prophylactic or therapeutic of sepsis; and
- d) Measuring the inhibition of said conversion of said TNF having a molecular weight of about 26,000 to one or more lower molecular weight TNF species.

6. A method as described in claim 5, wherein said TNF and TNF convertase are in solution with a pH of about 7.0.

7. A method as described in claim 6, wherein said TNF convertase is derived from HL60 cells.

8. A method as described in claim 7, wherein said one or more lower molecular weight TNF species have molecular weights selected from the group consisting of about 17,000, and 15,000.

9. A method as described in claim 8, wherein measuring the inhibition of said convertase comprises the steps of:

- a) Labelling said TNF with a molecular weight of about 26,000 with a suitable label;
- b) Treating said labelled 26 kd TNF with said convertase to convert said 26 kd TNF to said TNF having a molecular weight of about 17,000;
- c) Separating said TNF having a molecular weight of about 26,000 from said 17,000 molecular weight TNF; and
- d) Measuring said label present in said 17,000 molecular weight TNF or measuring the reduction of said label in the 26 kd species.

10. A method as described in claim 9, wherein said label is selected from the group consisting of radionuclides, fluors, or enzymes.

11. A method as described in claim 10, wherein said TNF having a molecular weight of about 26,000 and said 17,000 molecular weight TNF are separated by electrophoresis.

12. Prophylactics or therapeutics of sepsis that inhibit TNF convertase, said convertase being characterized in that it converts TNF 26 kd to one or more lower molecular weight TNF species.

13. The prophylactics or therapeutics of claim 12, wherein said prophylactics or therapeutics comprise anti-convertase antibody.

14. The prophylactics or therapeutics of claim 12, wherein said prophylactics or therapeutics comprise non-hydrolyzable muteins of TNF having a molecular weight of about 26,000.

15. The prophylactics or therapeutics of claim 14, wherein said muteins have valine at position 2 substituted or deleted.

16. The prophylactics or therapeutics of claim 14, wherein said muteins have valine at position 13 substituted or deleted.

17. The prophylactics or therapeutics of claim 14, wherein said muteins have valine at position 2 and valine at position 13 substituted or deleted.

18. The prophylactics or therapeutics of claim 14, wherein said muteins comprise a mutein wherein amino acids spanning -9 to 14 of 26 kd TNF are deleted.

19. Prophylactics or therapeutics of sepsis as described in claim 12, wherein said prophylactics or therapeutics comprise a peptide or protein having an amino acid sequence substantially similar to an amino acid sequence present on said 26 kd TNF to which said convertase binds.

20. Substantially purified TNF convertase that is inhibited by compounds selected from the group consisting of 3,4-dichloro-isocoumarin, elastinal and (1-((3-((acetyloxy)-7-methoxy-8-oxy-8-oxo-5-thio-1-azabicyclo [4.2.0] oct-2-en-2-yl) carbonyl) morpholine, S,S-dioxide, (6R-cis).

21. Substantially purified TNF convertase as described in claim 20, wherein said convertase is membrane associated and converts TNF having a molecular weight of about 26,000 to one or more lower molecular weight TNF species.

22. Substantially purified TNF convertase as described in claim 21, wherein said lower molecular weight TNF species has a molecular weight of about 17,000.

23. Antibody to TNF convertase, said antibody capable of binding to said convertase and either neutralizing the enzymatic activity of said convertase or preventing said convertase from binding to TNF, said convertase being characterized in that it converts TNF having a molecular weight of about 26,000 to one or more lower molecular weight TNF species.

24. Antibody as described in claim 23, wherein said lower molecular weight TNF species has a molecular weight of about 17,000.

25. Antibody according to claim 23, wherein said antibody is murine antibody.

26. Antibody according to claim 23, wherein said antibody is human antibody.

27. Antibody according to claim 23, wherein said antibody is recombinant antibody.

28. A method for treating a patient, either prophylactically or therapeutically, for sepsis comprising administering an effective amount of an inhibitor of TNF convertase, said convertase being characterized in that it converts 26 kd TNF to one or more lower molecular weight TNF species.

29. A method as described in claim 28, wherein said lower molecular weight TNF species has a molecular weight of about 17,000.

30. A method as described in claim 28, wherein said inhibitor comprises an anti-convertase antibody.

31. A method as described in claim 28, wherein said inhibitor comprises non-hydrolyzable muteins of TNF.

32. A method as described in claim 31, wherein said inhibitor comprises muteins shown in Table I.

33. A method as described in claim 31, wherein said inhibitor comprises muteins with valine at position 2 substituted or deleted, or valine at position 13 substituted or deleted.

34. A method as described in claim 31, wherein said inhibitor comprises muteins

35. A method as described in claim 31, wherein said inhibitor comprises a mutein with a deletion of amino acids -9 through 14 of 26 kd TNF.

36. A method as described in claim 28, wherein said inhibitor comprises a peptide or protein that competes with the 26 kd TNF for binding to the convertase.



37. Prophylactics or therapeutics of sepsis as described in claim 8, wherein said peptide comprises a dipeptide that competes for binding to TNF convertase with said 26 kd TNF and comprises the structure X-Ala-Val-Y wherein X and Y are amino acids.

38. Prophylactics or therapeutics of sepsis as described in claim 12, wherein said prophylactics or therapeutics comprise a peptide or protein having an amino acid sequence selected from the group consisting of Gln-Ala-Val-Arg-Ser-Ser-Ser, Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala, Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala-His-Val-Val-Ala, Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala-His-Val-Val-Ala, and Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro.

39. A method for treating a patient for AIDS, comprising administering to said patient an effective amount of an inhibitor of TNF convertase.

40. A method for treating a patient for autoimmune diseases, comprising administering to said patient an effective amount of an inhibitor of TNF convertase.

41. A method for treating a patient for autoimmune diseases as described in claim 40 wherein said autoimmune disease is arthritis.



2/4

-76


ATG	AGC	ACT	GAA	AGC	ATG	ATC	CGG	GAC	GTG	GAG	CTG
Met	Ser	Thr	Glu	Ser	Met	Ile	Arg	Asp	Val	Glu	Leu
GCC	GAG	GAG	GCG	CTC	CCC	AAG	AAG	ACA	GGG	GGG	CCC
Ala	Glu	Glu	Ala	Leu	Pro	Lys	Lys	Thr	Gly	Gly	Pro
CAG	GGC	TCC	AGG	CGG	TGC	TTG	TTC	CTC	AGC	CTC	TTC
Gln	Gly	Ser	Arg	Arg	Cys	Leu	Phe	Lue	Ser	Leu	Phe
TCC	TTC	CTG	ATC	GTG	GCA	GGC	GCC	ACC	ACG	CTC	TTC
Ser	Phe	Leu	Ile	Val	Ala	Gly	Ala	Thr	Thr	Leu	Phe
TGC	CTG	CTG	CAC	TTT	GGA	GTG	ATC	GGC	CCC	CAG	AGG
Cys	Leu	Leu	His	Phe	Gly	Val	Ile	Gly	Pro	Gln	Arg
GAA	GAG	TCC	CCC	AGG	GAC	CTC	TCT	CTA	ATC	AGC	CCT
Glu	Glu	Ser	Pro	Arg	Asp	Leu	Ser	Leu	Ile	Ser	Pro
CTG	GCC	CAG	GCA	GTG	AGA	TCA	TCT	TCT	CGA	ACC	CCG
Leu	Ala	Gln	Ala	Val	Arg	Ser	Ser	Ser	Arg	Thr	Pro
AGT	GAC	AAG	CCT	GTA	GCC	CAT	GTT	GTA	GCA	AAC	CCT
Ser	Asp	Lys	Pro	Val	Ala	His	Val	Val	Ala	Asn	Pro
CAA	GCT	GAG	GGG	CAG	CTC	CAG	TGG	CTG	AAC	CGC	CGG
Gln	Ala	Glu	Gly	Gln	Leu	Gln	Trp	Leu	Asn	Arg	Arg
GCC	AAT	GCC	CTC	CTG	GCC	AAT	GGC	GTG	GAG	CTG	AGA
Ala	Asn	Ala	Leu	Leu	Ala	Asn	Gly	Val	Glu	Leu	Arg
GAT	AAC	CAG	CTG	GTG	GTG	CCA	TCA	GAG	GGC	CTG	TAC
Asp	Asn	Gln	Leu	Val	Val	Pro	Ser	Glu	Gly	Leu	Tyr
CTC	ATC	TAC	TCC	CAG	GTC	CTC	TTC	AAG	GGC	CAA	GGC
Leu	Ile	Tyr	Ser	Gln	Val	Leu	Phe	Lys	Gly	Gln	Gly
TGC	CCC	TCC	ACC	CAT	GTG	CTC	CTC	ACC	CAC	ACC	ATC
Cys	Pro	Ser	Thr	His	Val	Leu	Leu	Thr	His	Thr	Ile
AGC	CGC	ATC	GCC	GTC	TCC	TAC	CAG	ACC	AAG	GTC	AAC
Ser	Arg	Ile	Ala	Val	Ser	Tyr	Gln	Thr	Lys	Val	Asn
CTC	CTC	TCT	GCC	ATC	AAG	AGC	CCC	TGC	CAG	AGG	GAG
Leu	Leu	Ser	Ala	Ile	Lys	Ser	Pro	Cys	Gln	Arg	Glu
ACC	CCA	GAG	GGG	GCT	GAG	GCC	AAG	CCC	TGG	TAT	GAG
Thr	Pro	Glu	Gly	Ala	Glu	Ala	Lys	Pro	Trp	Tyr	Glu
CCC	ATC	TAT	CTG	GGA	GGG	GTC	TTC	CAG	CTG	GAG	AAG
Pro	Ile	Tyr	Leu	Gly	Gly	Val	Phe	Gln	Leu	Glu	Lys
GGT	GAC	CGA	CTC	AGC	GCT	GAG	ATC	AAT	CGG	CCC	GAC
Gly	Asp	Arg	Leu	Ser	Ala	Glu	Ile	Asn	Arg	Pro	Asp
TAT	CTC	GAC	TTT	GCC	GAG	TCT	GGG	CAG	GTC	TAC	TTT
Tyr	Leu	Asp	Phe	Ala	Glu	Ser	Gly	Gln	Val	Tyr	Phe
GGG	ATC	ATT	GCC	CTG							
Gly	Ile	Ile	Ala	Leu							

157

FIG. 1C

3/4

FIG. 2 A B C D E F G



4/4

FIG. 3A




FIG. 3B



INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/03266

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: A 61 K 37/64, C 12 Q 1/37, C 12 N 9/50, C 07 K 15/28														
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black;">Classification System</td> <td style="border-bottom: 1px solid black;">Classification Symbols</td> </tr> <tr> <td style="height: 40px; vertical-align: bottom;">IPC5</td> <td style="vertical-align: bottom;">A 61 K; C 12 Q</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched⁸</div>			Classification System	Classification Symbols	IPC5	A 61 K; C 12 Q								
Classification System	Classification Symbols													
IPC5	A 61 K; C 12 Q													
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category *</th> <th style="width: 70%; border-bottom: 1px solid black;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 20%; border-bottom: 1px solid black;">Relevant to Claim No.¹³</th> </tr> <tr> <td style="vertical-align: top; text-align: center;">A</td> <td>EP, A1, 0308378 (YEDA RESEARCH AND DEVELOPMENT COMPNAY, LIMITED) 22 March 1989; see the whole document --</td> <td style="vertical-align: top; text-align: center;">1,3-27, 37-38</td> </tr> <tr> <td style="vertical-align: top; text-align: center;">A</td> <td>NATURE, Vol. 330, 1987, Kevin J. Tracey et al: "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia", see page 662 - page 664 --</td> <td style="vertical-align: top; text-align: center;">1,3-27, 37-38</td> </tr> <tr> <td style="vertical-align: top; text-align: center;">A</td> <td>Dialog Information Services, File 154, Medline 83-90, Dialog accession number 06520056, Kriegler M et a.: "A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF", Cell Apr 8 1988, 53 (1) p 45-53 --</td> <td style="vertical-align: top; text-align: center;">1,3-27, 37-38</td> </tr> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	EP, A1, 0308378 (YEDA RESEARCH AND DEVELOPMENT COMPNAY, LIMITED) 22 March 1989; see the whole document --	1,3-27, 37-38	A	NATURE, Vol. 330, 1987, Kevin J. Tracey et al: "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia", see page 662 - page 664 --	1,3-27, 37-38	A	Dialog Information Services, File 154, Medline 83-90, Dialog accession number 06520056, Kriegler M et a.: "A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF", Cell Apr 8 1988, 53 (1) p 45-53 --	1,3-27, 37-38
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
A	EP, A1, 0308378 (YEDA RESEARCH AND DEVELOPMENT COMPNAY, LIMITED) 22 March 1989; see the whole document --	1,3-27, 37-38												
A	NATURE, Vol. 330, 1987, Kevin J. Tracey et al: "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia", see page 662 - page 664 --	1,3-27, 37-38												
A	Dialog Information Services, File 154, Medline 83-90, Dialog accession number 06520056, Kriegler M et a.: "A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF", Cell Apr 8 1988, 53 (1) p 45-53 --	1,3-27, 37-38												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="height: 40px; vertical-align: bottom;">27th November 1990</td> <td style="vertical-align: bottom; text-align: center;">06 DEC 1990</td> </tr> <tr> <td style="border-bottom: 1px solid black;">International Searching Authority</td> <td style="border-bottom: 1px solid black;">Signature of Authorized Officer</td> </tr> <tr> <td style="height: 40px; vertical-align: bottom; text-align: center;">EUROPEAN PATENT OFFICE</td> <td style="vertical-align: bottom; text-align: center;">Mme N. KUIPER </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	27th November 1990	06 DEC 1990	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	Mme N. KUIPER				
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report													
27th November 1990	06 DEC 1990													
International Searching Authority	Signature of Authorized Officer													
EUROPEAN PATENT OFFICE	Mme N. KUIPER													

Form PCT/ISA/210 (second sheet) (January 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	Dialog Information Services, File 154, Medline 83-90, Dialog accession no. 05835610, Muller R et al: "Synthesis and maturation of recombinant human tumor necrosis factor in eukaryotic systems", FEBS Lett Mar 3 1986, 197 (1-2) p 99-104 --	1,3-27
A	EP, A1, 0334165 (F. HOFFMANN-LA ROCHE AG) 27 September 1989, see the whole document -- -----	20-27

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers * because they relate to subject matter not required to be searched by this Authority, namely:

*28-36, 39-41

See PCT Rule 39.1(iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claim numbers 2, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

1. Claims 1-19, 37, 38: Prophylactics and/or therapeutics of diseases caused by hormones or prohormones, especially 26 kdal. TNF, as well as methods for the identification of those prophylactics and therapeutics.
2. Claims 20-27: TNF convertase as well as antibodies to TNF convertase

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☒ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/US 90/03266

SA 38304

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 01/11/90
The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0308378	22/03/89	AU-D- 2206888 JP-A- 2000200	16/03/89 05/01/90
EP-A1- 0334165	27/09/89	AU-D- 3125289	21/09/89

For more details about this annex : see Official Journal of the European patent Office, No. 12/82

EPO F RM P0479